Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis
Paweł Łaniewski(University of Arizona), Melissa M. Herbst‐Kralovetz(University of Arizona), Denise J. Roe(University of Arizona), Haiyan Cui(Shandong Agricultural University), Dana M. Chase(Creighton University), Dominique Barnes(St. Joseph's Hospital and Medical Center), Alison Goulder(University of Arizona), David L. Greenspan(St. Joseph's Hospital and Medical Center), Bradley J. Monk(Creighton University)
Cited by 107
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Estrogen–gut microbiome axis: Physiological and clinical implications
|Maturitas|2017|948
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533
The microbiome and gynaecological cancer development, prevention and therapy
|Nature Reviews Urology|2020|463